Company Profile

XORTX Therapeutics Inc. is a pharmaceutical company, developing drug based products for two clinically advanced products – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Biotechnology

NAICS:
Pharmaceutical Preparation Manufacturing (325412)

SIC:
Pharmaceutical and Medicine Industry (3741)

Contact Information

Investor Relations
Allen Davidoff
CEO
T: 403-455-7727
adavidoff@xortx.com

Nick Rigopulos
Director of Communications
T: 617-901-0785
nick@alpineequityadv.com

Company Contact
XORTX Therapeutics Inc.
4000, 421 - 7th Avenue SW
Calgary, Alberta T2P 4K9
Canada
T: 403-455-7727
info@xortx.com